Back-Up Compounds and S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale

WELLESLEY HILLS, Mass., Nov. 1, 2011 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee for the Benefit of Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the back-up compounds and S1P1 lead compounds, assets generated by Epix Pharmaceuticals, Inc. and Amgen, will be offered December 8, 2011 in a sealed bid sale.  

Back-up Compounds --

A total of ~640 analogs were synthesized by Epix and/or Amgen chemists to explore the SAR of several chemical series including the two lead series:  benzofurans (AMG 277) and benzothiazoles (AMG 369).  Six of these compounds were profiled in a preliminary 4d non-GLP rat toxicology study based on their attractive potency, selectivity, ADME, and efficacy profiles.  Based on these results, four compounds were profiled further in a 14d non-GLP rat toxicology study and two of these compounds were profiled in a monkey 14d non-GLP toxicology study.  

Assets included in the sale include preclinical and toxicology data related to AMG 277, AMG 369 and six backup compounds, existing inventory of these compounds (API), and related patent portfolio.

Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's office -- [email protected] or 781-237-8840; upon receipt of the executed CDA, applicants will receive a bid package, to be completed and returned by December 8, 2011.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts.  He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.  His most recent Assignments for the Benefit of Creditors in the biotech filed include Spherics, Inc., ActivBiotics, Inc., Prospect Therapeutics, Inc. and Source MDx.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or [email protected].

SOURCE Joseph F. Finn, Jr., C.P.A.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED